⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Table S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Xiu-Zhi Zhu Hu-Yun-Long Zhang Yi-Fan Zhou Yi-Yu Chen Tong Fu Ming-Liang Jin Ya-Xin Zhao Yi-Fan Xie Xiaohua Zeng Xi Jin Yi‐Zhou Jiang Zhi‐Ming Shao

View at Publisher

Ask AI

Bookmark

Share

Key Points

HR+/HER2− breast cancer treatment improves with subtyping-directed precision therapy, indicating personalized strategies.
Precision treatment criteria for matched and unmatched groups enhance therapy outcomes in breast cancer patients.
This approach involves subtyping methods to determine optimal treatment pathways for better patient outcomes.
The findings may support shifts away from traditional one-size-fits-all therapy to more tailored interventions.

Implication

Subtyping-directed precision treatment enhances outcomes in HR+/HER2− breast cancer, suggesting better therapy criteria.

Abstract

Criteria for matched and unmatched groups determined according to SNF subtyping-directed precision treatment strategy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcad2 https://doi.org/10.1158/0008-5472.30363442

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
2Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
3Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
4Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
5Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025

Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025